H4: the device was manufactured from may 5, 2020 - may 6, 2020.H10: the actual device was received for evaluation containing 27ml of residual drug fluid in the device.A visual inspection was performed using the naked eye which did not identify any abnormalities that could have contributed to the reported condition.A functional flow rate test was performed and found to be within the product specification range.The reported condition was not verified.A batch review was conducted and there were no deviations found related to this reported condition during the manufacture of this lot.Should additional relevant information become available, a supplemental report will be submitted.
|